of Week Home
16 December 2011 - Case of the Week #227
All cases are archived on our website. To view them sorted by number, diagnosis or category, visit our Home Page and click on the Case of the Week button on the left hand side. To subscribe or unsubscribe to the Case of the Week or our other email lists, click here.
Thanks to Dr. Semir Vranic, Clinical Center of the University of Sarajevo (Bosnia), for contributing this case. To contribute a Case of the Week, follow the guidelines on our Case of the Week page.
CancerTYPE ID is a standardized, objective molecular test based on the differential expression of 92 genes, that classifies tumors by matching the gene expression pattern of a patients tumor tissue to a database of known tumor types and histological subtypes.
CancerTYPE IDs database includes 2,206 tumors from multiple tumor banks, selected to provide broader and deeper representation of the heterogeneity of tumors. The 92-gene assay does not overlap with IHC markers, providing complementary data to standard tumor diagnosis.
CancerTYPE ID uses real-time reverse transcription polymerase chain reaction (RT-PCR). A very low copy number of RNA molecules can be detected, thus reducing the sample tissue required for testing. Testing is conducted and results are generated at bioTheranostics' CAP-accredited, CLIA-certified laboratory.
For more information, click here.
(1) Do you want to motivate students from Detroit to be the best they can be? PathologyOutlines.com sponsors a charity, The Detroit College Promise, which provides scholarships to Detroit students simply for living in Detroit, attending a Detroit Public School, and taking a pledge. To date, over 20,000 students have registered. 100% of all funds contributed are used for scholarships, because PathologyOutlines.com covers all the overhead (even credit card fees). Click here to contribute or for more information.
(2) We continue to have record website traffic, with 16,190 visits on 13 December 2011. Please continue to let us know what we can do to make our website more useful to you.
(3) We are currently updating these chapters: CD Markers, Drugs of interest to pathologists, Kidney tumor-cysts, children, adult benign, Placenta and Stains.
(4) Dr. Pernick has posted a research paper, The Laws of Complexity and Self-organization: A Framework for Understanding Neoplasia. This is based on an exciting new view of biology developed by Dr. Stuart Kauffman, the winner of a MacArthur Fellowship. Your comments are welcome to NatPernick@hotmail.com.
Case of the Week #227
A 60 year old woman with no history of malignancy, kidney disease or other medical disorders presented with a tumor mass in the upper outer quadrant of her left breast measuring 30x25 mm. Previous mammography revealed massive calcification with a benign appearance. A wide excision was performed. Frozen section revealed no definite diagnosis.
What is your diagnosis?
Osseous metaplasia of the breast
The specimen contains well-formed bone tissue without associated neoplasia.
Osseous metaplasia is uncommon. It is associated with benign lesions, including cholesterol granuloma (Pathol Res Pract 2008;204:353), fibroadenoma (Radiology 1989;172:671), fasciitis ossificans (Pathol Res Pract 2007;203:737, Arch Pathol Lab Med 2004;128:e29), lipogranuloma (Yonsei Med J 2011;52:373), radiation therapy (Br J Radiol 2002;75:460), saline implants (Plast Reconstr Surg 2001;107:356) and silicone implants (Ann Plast Surg 1998;41:348).
Osseous metaplasia is also associated with metaplastic carcinoma and other invasive subtypes (Breast 2008;17:314, Am J Surg Pathol 2009;33:534), as well as osteosarcoma of the breast (Cases J 2008 Aug 9;1(1):80).
This disorder is benign, but it is important to exclude a possible associated malignancy, which may not be evident on a core biopsy.
Nat Pernick, M.D., President
and Liz Parker, B.A., Associated Medical Editor
30100 Telegraph Road, Suite 408
Bingham Farms, Michigan (USA) 48025
Alternate email: NatPernick@gmail.com